KLUS Pharma Attending BIO Partnering at JPM KLUS Pharma will attend BIO Partnering at JPM on Jan 11-15. Introduction and new updates are expected for several programs that are under...
IND for KL-A289 is Approved in China In August 2020, the IND for KL-A289 (anti-LAG-3 mAb) was approved by the NMPA to begin a Phase 1 clinical trial in China. LAG-3 has recen...
